
    
      -  Prospective, interventional, randomized, double-blind, placebo-controlled trial.

        -  Clinical setting (tertiary University Hospital).

        -  Investigator-driven, no pharmaceutical sponsor.

        -  Lung transplant recipients.

        -  Add-on of study-drug (placebo or montelukast) to 'standard of care'

        -  1:1 inclusion ratio (placebo:montelukast).

        -  Randomisation at diagnosis of chronic rejection after informed consent.
    
  